Previous 10 | Next 10 |
Dare Bioscience (DARE): Q3 GAAP EPS of -$0.24 misses by $0.06.Cash and cash equivalents of ~$5.4M.Press Release For further details see: Dare Bioscience EPS misses by $0.06
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the third quarter ended September 30, 2020 and provided a company update. “We made great progress towa...
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 12, 2020, to review ...
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2020 BIO Investor Forum, which will be hel...
Daré Bioscience ([[DARE]]) receives ~$0.9M in funding under the current grant from the Bill & Melinda Gates Foundation.The grant payment will support ongoing development activities for Daré’s investigational user-controlled, long-acting reversible contraceptive, DARE-LARC...
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received the final approximately $0.9 million in funding under the current grant from the Bill & Melinda Gates Foundation. The gr...
Introduction Dare Bioscience ( DARE ) is an interesting small biotech company, which develops new treatment methods for large markets, such as bacterial vaginosis, hormone-free contraceptive, and Female Sexual Arousal Disorder. However, despite the large potential market, it is still crucial...
SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, Daré’s President and CEO, will participate in two upcoming virtual conferences: Women...
Daré Bioscience (NASDAQ: DARE ) inks a three-year agreement with Avomeen under which the latter will be its preferred provider of product development lab services. More news on: Daré Bioscience, Inc., Healthcare stocks news, Read more ...
SAN DIEGO and ANN ARBOR, Mich., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Avomeen, an accredited, independent contract research, development, and manufacturing organization specializing in...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...